Jan Rutherford

Jan is a partner and member of SEP’s Investment Committee.

Jan is a partner and member of SEP’s Investment Committee.

With over twenty years’ investment experience, Jan retains a particular interest in healthcare and life sciences software and solutions. She sits on the responsible investment committee and is also a co-founder of SEP’s Women in Tech Leadership network which aims to increase female representation at board level in technology companies.

Jan jointly led SEP’s investment in Dotmatics, a global scientific informatics software provider (acquired by Insightful Science). Other investments have included digital patient engagement platform provider, ExcoInTouch (acquired by ERT, now Clario) and cancer therapeutics company BioVex,($1B exit to Amgen).

Jan has been deeply involved in the European life sciences and technology industries for over 30 years, having previously held operational and commercial roles with Merck, Novartis and IQVIA before moving into her first investment role in 2000 with Dresdner Kleinwort Capital’s global life sciences team. She holds a degree in pharmacy and an MBA and is a Member of the Royal Pharmaceutical Society (MRPharmS).

Outside SEP, Jan is a Trustee of the National Deaf Children’s Society.